Your browser doesn't support javascript.
Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K.
Di Giacomo, Simone; Mercatelli, Daniele; Rakhimov, Amir; Giorgi, Federico M.
  • Di Giacomo S; Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
  • Mercatelli D; Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
  • Rakhimov A; Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
  • Giorgi FM; Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
J Med Virol ; 93(9): 5638-5643, 2021 09.
Article in English | MEDLINE | ID: covidwho-1363682
ABSTRACT
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have emerged, posing a renewed threat to coronavirus disease 2019 containment and to vaccine and drug efficacy. In this study, we analyzed more than 1,000,000 SARS-CoV-2 genomic sequences deposited up to April 27, 2021, on the GISAID public repository, and identified a novel T478K mutation located on the SARS-CoV-2 Spike protein. The mutation is structurally located in the region of interaction with human receptor ACE2 and was detected in 11,435 distinct cases. We show that T478K has appeared and risen in frequency since January 2021, predominantly in Mexico and the United States, but we could also detect it in several European countries.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Genome, Viral / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Europa / Mexico Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.27062

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Genome, Viral / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Europa / Mexico Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.27062